Title: Johnson & Johnson (NYSE_JNJ) Shares React as FDA Grants Multiple Designations to Nipocalimab
Date (YYYY-MM-DD hour-min):2025-04-09 18-09
URL: https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-shares-180948855.html?.tsrc=rss
Oops, something went wrong
Tip: Try a valid symbol or a specific company name for relevant results
Oops, something went wrong
How the bond market helped make Trump blink on tariffs
The Dow fell 1,000 points, and the S&P 500 and Nasdaq were crushed as stocks resumed a tariff-fueled sell-off
Trump's total tariff on China is actually 145%, the White House said, an amount higher than the 125% previously reported
Stocks hit session lows as focus turned to the US-China trade war. The Dow lost over 1,200 points, and the Nasdaq plunged 4.5%.
The Dow plummeted 900 points and the Nasdaq plunged over 3% as a tariff-fueled sell-off picked up speed again.
Stocks plummet as Wall Street's euphoria from Trump's tariff pause gets a reality check
Inflation unexpectedly tumbled in March, and core CPI rose at its slowest pace in four years.
The EU matched Trump's 90-day pause on tariffs to 'give negtiations a chance.' See our live updates.
The 'Trump put' makes an appearance
March's report could be last time investors see inflation easing. Here's what to expect.
Stocks wanted one thing from Trump after his shocking tariff announcement last week. They finally got it today.
Stocks staged a wild rally after Trump's tariff reversal. The Dow gained near 3,000 points and the S&P 500 had its best day since 2008.
Trump nodded to market turbulence as a factor in his 'reciprocal' tariff pause, saying investors were 'yippy' and 'afraid'
The Nasdaq was up 10%, aiming for its biggest gain since 2008, after Trump paused some tariffs. The Dow soared 2,500 points.
Trump unilaterally raises tariff rate on China to 125%, pauses 'reciprocal' tariffs on other countries
The major indexes rocketed higher after Trump announced a '90-day pause on tariffs for most countries.
Investors grapple with bond chaos as long-term yields soar following Trump's sweeping tariffs
Trump tries to reassure Americans as markets reel from tariff shocks
JPMorgan's Dimon: US recession now a 'likely outcome'
Dow slides, Nasdaq rises after China strikes back against Trump's tariffs
China strikes back by raising tariff on US goods to 84% after Trump's massive duties take effect
What rankles Elon Musk the most — and what he actually likes — about Trump's trade approach
A diminished ‘Magnificent 7’ tests Big Tech’s role in the market
Trump tariffs live updates: US moves forward with 104% China tariffs, other 'reciprocal' duties go into effect
Low mortgage rates from tariff pain? Don't count on it.
Bill Ackman is waging a public campaign to sway Trump's tariffs. Here's what the billionaire says should happen next.
Tariff-fueled losses for the megacaps have topped $2 trillion, as Tesla and Apple led Tuesday's sell-off
Stocks completed a remarkable U-turn, with the Dow ending 300 points lower as Trump's tariffs sparked more volatility
The S&P 500 and Nasdaq turned red after an early rally, as the White House said Trump would move forward with 104% China tariffs.
Markets are wrestling with a mystery: What exactly does Trump want from tariff talks?
Dow, S&P 500, Nasdaq surge in Wall Street rebound as hopes for Trump tariff deals get a boost
Wall Street got a preview of what could stop the tariff turmoil
'No signal, lots of noise': Sell-off cools down as Trump's tariffs drive wild swings in stock market
Some of Trump's closest allies, including Elon Musk and Bill Ackman, are starting to raise questions about his tariff team
The Trump stock market crash will hurt Main Street more than Wall Street
Dow sinks 350 points, S&P 500 falls for third straight day as tariffs send stocks on roller-coaster ride
BlackRock's Fink says most CEOs tell him 'we are probably in a recession right now'
Wall Street bulls are ripping up their forecasts as the market's tariff-fueled meltdown 'projects negative outcomes to infinity'
Trump threatens additional tariffs on China if it doesn't scrap its plans for retaliation
Stocks whipsawed in volatile trading as investors sought clarity on tariff developments. See the latest updates.
Dow, S&P 500, Nasdaq plummet as Trump tariff rout set to continue
Jamie Dimon warns of slower growth, higher inflation as tariffs add 'one large additional straw on the camel’s back'
Dow, S&P 500, Nasdaq futures plunge as Trump tariff rout gets set to escalate
Trump says markets may have to 'take medicine' as stock futures plummet
Analysts say stocks have 'ample space' to keep selling off as Trump and top advisers dig in on tariffs
Stock futures plunge as Trump tariff rout looks set to intensify
Homebuyers waiting for lower mortgage rates may wonder if rates will ever get to 3% again. Here's what to know.
Opinion: There are too many unknowns to be able to model a clean market forecast right now.
Builders sitting on a pile of unsold homes are slashing prices and offering mortgage rate deals
Trump administration officials appeared on Sunday shows as markets brace for more turmoil
Johnson & Johnson announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis, which were significant events during the quarter. Additionally, the company's ongoing regulatory strides, including new designations for nipocalimab, offered a robust pipeline outlook. However, despite a 5% stock increase in the last quarter, JNJ's performance remained largely aligned with market movements, which experienced a volatile phase due to broad economic uncertainties and tariff concerns. These developments provided some support against a backdrop of overall market downturns.
We've spotted 1 possible red flag for Johnson & Johnson you should be aware of.
AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
The compelling results from Johnson & Johnson's Phase 3 study on nipocalimab could significantly bolster its portfolio in treating generalized myasthenia gravis, potentially leading to increased market confidence and improved revenue streams. This progress aligns with their strategic focus on expanding treatment options, which may positively influence revenue and earnings forecasts. Over the past five years, JNJ's total return, including dividends, was 18.19%, indicating solid long-term growth. In the last year, JNJ surpassed the US Pharmaceuticals industry, which saw an 11.5% decline, demonstrating resilience against broader industry challenges.
Despite the promising data and a subsequent 5% stock increase last quarter, the stock remains priced below the consensus price target of $171.11, reflecting a 9.4% potential upside from its current US$153.25 level. These share price dynamics suggest investor caution amid macroeconomic pressures. As analysts project revenue to grow 2.9% annually with improved profit margins, any positive regulatory developments related to nipocalimab could further justify the stock moving towards its price target, potentially enhancing the company's market position and shareholder value.
Explore historical data to track Johnson & Johnson's performance over time in our past results report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NYSE:JNJ.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Bond-market participants got a major surprise Wednesday afternoon when the Treasury Department’s $39 billion auction of 10-year notes produced very strong demand, helping to alleviate concerns that buying interest would fail to hold up given tariff-driven volatility.
A double dose of good news gave investors hope for the future.
Nvidia (NASDAQ: NVDA) is enabling the rapid adoption of AI.  Its graphics processing units (GPUs) are used in everything from playing video games to powering the largest data centers, where the AI magic happens.  CEO Jensen Huang will go down as one of the great business leaders of the 21st century.
The Invesco QQQ Trust tumbled Thursday after surging 12% yesterday following President Trump's announcement of a 90-day pause on many tariffs. Monitor these crucial chart levels.
Trump's tariffs may not hit US real estate investment trusts (REIT) head on, but according to a new note from Bloomberg Intelligence, if the economy cools and rates drop, rates could feel the ripple effect. Bloomberg Intelligence Jeffrey Langbaum has more on the story.
Shares of several major pharmaceutical companies slumped Wednesday morning as President Donald Trump threatened tariffs on the industry.
Here are the best Bitcoin ETFs, including how much you’ll pay to invest in them.
You've worked hard ever since you got that first job as a teenager. Over the years, you've gone from scooping ice cream to leading project teams, and you've built a solid financial foundation. As...
Here are the top Nasdaq ETFs and key things you need to look for.
It might not be as much as you think.
Tip: Try a valid symbol or a specific company name for relevant results
Sign in to access your portfolio
Try again.
